SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01700582

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) Benefiting From a Molecular Test on the Hospital Platforms of Molecular Genetics.

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).

NCT01700582 Carcinoma, Non-Small-Cell Lung ALK Gene Mutation KRAS Gene Mutation BRAF Gene Mutation
MeSH: Carcinoma, Non-Small-Cell Lung
HPO: Non-small cell lung carcinoma


Primary Outcomes

Description: Number of patients with EGF-R gene mutation

Measure: EGF-R gene mutation in nationwide cohort

Time: 1 Year

Secondary Outcomes

Description: Number of patients with K-RAS gene mutation

Measure: K-RAS gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with EML4-ALK translocation

Measure: EML4-ALK translocation in nationwide cohort

Time: 1 year

Description: Number of patients with BRAF gene mutation

Measure: BRAF gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with HER2 gene mutation

Measure: HER2 gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with PI3K gene mutation

Measure: PI3K gene mutation in nationwide cohort

Time: 1 year

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T790M

Regarding stage IV non-squamous NSCLC patients, 7 biomarkers are assessed including activating EGFR mutations, EML4-ALK translocation and EGFR T790M, KRAS, BRAF, HER2 and PI3KCA mutations. --- T790M ---



HPO Nodes


HPO:
Non-small cell lung carcinoma
Genes 2
TP53 BAP1